Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Follow Smart Money Into Vertex Pharmaceuticals Incorporated (VRTX)?

Page 1 of 2

There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each year by hiring the best and the brightest to do research on stocks, including small cap stocks that big brokerage houses simply don’t cover. Because of Carl Icahn and other elite funds’ exemplary historical records, we pay attention to their small cap picks. In this article, we use hedge fund filing data to analyze Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Vertex Pharmaceuticals Incorporated has experienced an increase in activity from the world’s largest hedge funds in recent months, as 51 funds from our database reported stakes as of September 30, up by six on the quarter. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Illumina, Inc. (NASDAQ:ILMN), Archer Daniels Midland Company (NYSE:ADM), and Cardinal Health, Inc. (NYSE:CAH) to gather more data points.

Follow Vertex Pharmaceuticals Inc / Ma (NASDAQ:VRTX)
Trade (NASDAQ:VRTX) Now!

At the moment there are numerous formulas market participants put to use to assess stocks. A duo of the less utilized formulas are hedge fund and insider trading moves. Our researchers have shown that, historically, those who follow the top picks of the elite money managers can outperform the S&P 500 by a healthy margin (see the details here).

Keeping this in mind, we’re going to check out the new action encompassing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Hedge fund activity in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

At Q3’s end, a total of 51 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 13% from one quarter earlier. With hedge funds’ sentiment swirling, there exists an “upper tier” of key hedge fund managers who were boosting their stakes considerably (or already accumulated large positions).

When looking at the institutional investors followed by Insider Monkey, Ken Griffin’s Citadel Investment Group has the most valuable position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), worth close to $244.6 million, comprising 0.2% of its total 13F portfolio. Sitting at the No. 2 spot is Millennium Management, led by Israel Englander, holding a $164.5 million position; 0.3% of its 13F portfolio is allocated to the stock. Other professional money managers with similar optimism consist of Andreas Halvorsen’s Viking Global, John Lykouretzos’s Hoplite Capital Management and Phill Gross and Robert Atchinson’s Adage Capital Management.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!